Literature DB >> 12003962

Role of newer fluoroquinolones in lower respiratory tract infections.

H Lode1, M Allewelt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12003962     DOI： 10.1093/jac/dkf024

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.

Authors:  Hee-Soo Park; Hyun-Joo Kim; Min-Jung Seol; Dong-Rack Choi; Eung-Chil Choi; Jin-Hwan Kwak
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

3.  Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.

Authors:  Carmen Puig; José Manuel Tirado-Vélez; Laura Calatayud; Fe Tubau; Junkal Garmendia; Carmen Ardanuy; Sara Marti; Adela G de la Campa; Josefina Liñares
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

4.  In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001.

Authors:  Rea Krausse; Uwe Ullmann
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

5.  Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.

Authors:  Marc Leone; Jacques Albanèse; Emmanuelle Sampol-Manos; Nicolas Simon; Bruno Lacarelle; Bernard Bruguerolle; Claude Martin
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia.

Authors:  Solomon Hambisa; Sileshi Belew; Sultan Suleman
Journal:  Drug Des Devel Ther       Date:  2019-04-17       Impact factor: 4.162

7.  Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.

Authors:  Konstantinos Gourgoulianis; Alessandro Ruggieri; Alessandra Del Vecchio; Fabrizio Calisti; Alessandro Comandini; Giovanna Esposito; Giorgio Di Loreto; Nikolaos Tzanakis
Journal:  Can Respir J       Date:  2021-05-25       Impact factor: 2.409

8.  Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.

Authors:  Roshan Siva; Mona Bafadhel; William Monteiro; Christopher E Brightling; Ian D Pavord
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.